Trial Profile
A Phase II Study of TKI258 in Patients With Castration-resistant Prostate Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Dovitinib (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Biomarker; Therapeutic Use
- 11 Oct 2016 Results presented at the 41st European Society for Medical Oncology Congress
- 11 Oct 2016 Status changed from recruiting to completed.
- 09 Jan 2013 New trial record